Butyrate supplements improve efficacy in patients with moderate to severe chronic spontaneous urticaria, A randomized, double-blind, placebo-controlled trial

Phase 3

Recruiting

• Conditions: chronic urticaria; butyrate; UAS7

• Registration Number: TCTR20220302003
• Lead Sponsor: Department of Medicine of Phramongkutklao hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-02
• Study Completion: 2022-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

chronic urticaria patients who symptoms do not improve with second generation antihistamine drug

Exclusion Criteria

1. History of butyrate allergy
2. Immunocompromised patient , psychiatric , kidney impairment and hepatic impairment patient
3. Patient need to take other medicine for chronic urticaria treatment other than second generation antihistamine drug eg. H2 antagonists , leukotriene receptor antagonists, first-generation antihistamine, cyclosporine or omalizumab
4. Pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of butyrate supplement in chronic urticaria treatment time at end of intervention Dermatology Life Quality Index (DLQI) and Urticaria activity score7 (UAS7)

Secondary Outcome Measures

Name	Time	Method
aboratory improvement in chronic urticaria patient after butyrate supplement time at end of intervention D dimer , CRP , dysfunctional Treg, basophil activation test